¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"flow related enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enhancement medium
    Áõ°­¹èÁö
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • aqueous flow
    ¹æ¼öÈ帧
  • axial flow
    Ãà·ù, ÃàÈ帧
  • axoplasmic flow
    Ãà»èÇüÁúÈ帧
  • back flow
    ¿ª·ù, °Å²ÜÈ帧
  • blood flow
    1. Ç÷·ù 2. Ç÷·ù·®
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    1. Ç÷·ù·® 2. Ç÷·ù¼Óµµ
  • bulk flow
    µ¢ÀÌÈ帧, ¿ëÀûÈ帧
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • continuous flow analyzer
    ¿¬¼ÓÈ帧ºÐ¼®±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement medium
    Áõ°­¹èÁö
  • immunologic enhancement
    ¸é¿ª±âÇÇÀ¯µµ, ¸é¿ªÃËÁø
  • inflow enhancement
    À¯ÀÔÁõ°­
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • thermal enhancement ratio
    ¿Â¿­Áõ°¨ºñ
  • aqueous flow
    ¹æ¼öÈ帧
  • axial flow
    ÃàÈ帧, Ãà·ù
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­(åÕпý­ñòË­)
  • posterior echo enhancement
    ÈÄ¹æ ¿¡ÄÚ Áõ°­, ÈÄ¹æ ¸Þ¾Æ¸®Áõ°­
  • posterior echo enhancement
    ÈĹæ (ý­Û°) ¿¡ÄÚ Áõ°­ (ñòË­), ÈĹæ (ý­Û°) ¸Þ¾Æ¸® ?
  • rapid acquisition with relaxation enhancement (RARE)
    ±Þ¼Ó ȹµæ ÀÌ¿Ï Áõ°­
  • related
    ±ÙÄ£(ÐÎöÑ)ÀÇ.
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • Flow
    À¯·®(êüÕá), È帧
  • Flow-limited exchange
    À¯·®Á¦Çѱ³È¯(ð¤ùÚÎßüµ)
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • Pulsatile flow
    ¹Úµ¿ Ç÷·ù (ÚÑÔÑ úì×µ)
  • RPF => renal plasma flow
    ½ÅÇ÷Àå·ù(·®)
  • air flow
    ±â·ù(Ë»Ëô).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • opioid-related disorder
    ¾ÆÆí¾çÁ¦Á¦ °ü·ÃÀå¾Ö(μ֤î¡äô)(º´)
  • parathyroid hormone-related peptide
    ºÎ°©»ó¼±(ÜùË£ßÒàÍ)È£¸£¸ó¿¬°ü(¡­æáμ)ÆéŸÀ̵å
  • polysubstance-related disorder
    º¹ÇÕ¹°Áú°ü·ÃÀå¾Ö(º´)
  • related
    ±ÙÄ£(ÐÎöÑ)ÀÇ.
  • sleep-related disorders
    ¼ö¸é°ü·ÃÀå¾Ö(º´)
  • steroid-related disorders
    ½ºÅ×·ÎÀÌµå °ü·ÃÀå¾Ö(º´).
  • stress-related disorders
    ½ºÆ®·¹½º °ü·ÃÀå¾Ö(º´).
  • tobacco-related disorders
    Åä¹ÙÄÚ(´ã¹è)°ü·ÃÀå¾Ö(~º´).
  • transfusion-related
    ¼öÇ÷-¿¬°üÀÇ
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement ratio
    Á¶¿µ Áõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­ ½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬ Áõ°­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • flow birefringence
    È帧 º¹±¼Àý(ÜÜÏÝï¹)
  • flow cell
    È帧 ½Ç(ãø)
  • flow dichroism
    È帧 ÀÌ»ö¼º(ì£ßäàõ)
  • flow method
    È긲¹ý(Ûö)
  • flow quenching
    È帧 ¼Ò±¤(á¼ÎÃ)
  • gas-flow counter
    °³½º È긲 °èÃø±â(ͪö´Ðï)
  • gradient-flow method
    ±¸¹è(ÎþÛÕ)-È帧¹ý(Ûö)
  • laminar flow
    Ãþ·ù(öµ×µ)
  • pulsatile flow
    ¸Æ·ù(Øæ×µ)
  • rapid flow kinetics
    ±Þ·ù¿ªµ¿ÇÐ(Ðá×µæ³ÔÑùÊ)
  • rapid flow technique
    ±Þ·ù¼ú(Ðá×µâú)
  • sedimentation field flow fractionation
    ħ°­Àå(öØË½íÞ) È帧ºÐȹ¹ý(ÝÂüñÛö)
  • stopped flow technique
    È帧Á¤Áö ¼ú(ïÎò­âú)
  • upward flow
    »óÇâ(ß¾ú¾) È帧
  • windowless gas flow counter
    ¹«Ã¢(Ùíóë) °¡½º È帧 °èÃø±â(ͪö´Ðï)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • posterior echo enhancement
    ÈĹ濡ÄÚÁõ°­, ÈĹæ¸Þ¾Æ¸®Áõ°­
  • proton relaxation enhancement
    ¾çÀÚÀÌ¿ÏÁõ°­
  • rapid acquisition with relaxation enhancement [=RARE]
    ÀÌ¿ÏÁõ°­±Þ¼Óȹµæ
  • rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • ring enhancement
    ȯ»óÁ¶¿µÁõ°­
  • sonic enhancement
    À½ÆÄÁõ°­
  • back flow
    ¿ª·ù
  • blood flow
    Ç÷·ù·®
  • bulk flow
    µ¢¾î¸®È帧
  • cerebrospinal fluid flow void sign
    ³úô¼ö¾×È帧¼Ò½Ç¡ÈÄ
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • color Doppler flow mapping
    »öµµÇ÷¯Ç÷·ùÁöµµÈ­
  • color flow imaging
    »öÇ÷·ù¿µ»ó
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • counter current flow
    ¿ªÈ帧, °Å²Ù·ÎÈ帧, ¿ª·ù
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MBF medullary blood flow; muscle blood flow; myocardial blood flow
PBF peripheral blod flow; placental blood flow; pulmonary blood flow
ARC accelerating rate calorimetry; acquired immunodeficiency syndrome-related complex; active renin conc...
CRS Carroll rating scale for depression; catheter-related sepsis; caudal regression syndrome; cervical s...
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MET Motivational Enhancement Therapy
NOESY Nuclear Over-hauser enhancement spectroscopy
NOE Nuclear Overhauser Enhancement
OER Oxygen Enhancement Ratio
RARE Rapid Acquisition with Relaxation Enhancement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µ Áõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µ Áõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • ring enhancement
    ȯ»ó Á¶¿µ Áõ°­
  • sonic enhancement
    À½ÆÄ Áõ°­
  • air flow
    ±â·ù
  • aqueous flow
    ¹æ¼ö È帧, ¹æ¼ö·ù
  • blood flow pattern
    Ç÷·ù ¾ç»ó
  • blood flow velocity
    Ç÷·ù ¼Óµµ
  • bulk flow
    µ¢¾î¸® È帧
  • color Doppler flow mapping
    »ö µµÇ÷¯ Ç÷·ù ÁöµµÈ­
  • color flow imaging
    »öÇ÷·ù ¿µ»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
AIDS-related virus An obsolete term for human immunodeficiency virus.
(05 Mar 2000)
alcohol-related disorders Mental disorders related or resulting from abuse or mis-use of alcohol.
(12 Dec 1998)
amphetamine-related disorders Disorders related or resulting from use of amphetamines.
(12 Dec 1998)
angiotensin-related carboxypeptidase <enzyme> Rat and bovine brain synaptosomal enzyme can hydrolyze angiotensin I to des-leu angiotensin I, but no further
Registry number: EC 3.4.-
Synonym: angiotensin-specific carboxypeptidase
(26 Jun 1999)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
MAK-related kinase <enzyme> A cdc2-related serine/threonine kinase; shows 87% idnetity to the male-germ cell associated kinase (mak); mw 66 kD; genbank d26178
Registry number: EC 2.7.10.-
Synonym: mrk kinase
(26 Jun 1999)
receptors, calcitonin gene-related peptide Cell surface proteins that bind calcitonin gene-related peptide (cgrp) with high affinity and trigger intracellular changes which influence the behaviour of cells. Cgrp receptors are present in both the central nervous system and the periphery and are not the same as calcitonin receptors.
(12 Dec 1998)
related 1. Allied by kindred; connected by blood or alliance, particularly by consanguinity; as, persons related in the first or second degree.
2. Standing in relation or connection; as, the electric and magnetic forcec are closely related.
3. Narrated; told.
4. Same as Relative.
Source: Websters Dictionary
(01 Mar 1998)
cdc2+-CDC28-related protein kinase <enzyme> From rice; key enzyme for cell cycle regulation in eukaryocytes; belongs to serine-threonine kinase subfamily
Registry number: EC 2.7.10.-
Synonym: cdc2-cdc28-pk, cdc2-cdc28-rp kinase
(26 Jun 1999)
glucose related protein <protein> One of the stress related proteins: identical to endoplasmin.
(18 Nov 1997)
risks, obesity-related Obesity increases the risk of developing a number of diseases including: type 2 (adult-onset) diabetes high blood pressure (hypertension) stroke (cerebrovascular accident or cva) heart attack (myocardial infarction or mi) heart failure (congestive heart failure) cancer (only certain forms such as prostate and colon cancer) gallstones and gall bladder disease (cholecystitis) gout and gouty arthritis osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back sleep apnea (failure to breath normally during sleep, lowering blood oxygen) pickwickian syndrome (obesity, red face, underventilation, and drowsiness)
(12 Dec 1998)
cocaine-related disorder <psychiatry> Disorders related or resulting from use of cocaine.
(12 Dec 1998)
movement-related pain <symptom> A type of breakthrough pain that is related to specific activity, such as eating, defecation, socialising or walking. Also referred to as incident pain.
(16 Dec 1997)
criterion-related validity The degree of effectiveness with which performance on a test or procedure predicts performance in a real-life situation; e.g., a good correlation between a score on an intelligence test such as the Scholastic Aptitude Test and one's 4-year college grade point average.
(05 Mar 2000)
H1-related protein-tyrosine phosphatase <enzyme> Has tyrosine and threonine/serine phosphatase activities
Registry number: EC 3.1.3.-
Synonym: vaccinia virus h1-related protein tyrosine phosphatase, vhr ptpase, vh-ptp13
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á